Trials / Recruiting
RecruitingNCT07053358
Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients
An Exploratory Clinical Study Evaluating LX111 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD)
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to evaluate the safety and efficacy of LX111 treatment of nAMD. This study will enroll subjects aged ≥ 50 vears old to receive a single unilateral intravitreal (lVT) injection of LX111 to evaluate its safety and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | LX111 Injection | Qualified subjects will receive a single unilateral intravitreal injection of LX111 at Day 0. |
Timeline
- Start date
- 2025-07-02
- Primary completion
- 2026-11-23
- Completion
- 2029-12-30
- First posted
- 2025-07-08
- Last updated
- 2026-03-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07053358. Inclusion in this directory is not an endorsement.